Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Braftovi (Encorafenib) plus Mektovi (Binimetinib)

September 18, 2018 Technology Prognosis

Braftovi (encorafenib) plus Mektovi (binimetinib) is new BRAF-MEK inhibitor combination regimen approved by the Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Ajovy (Fremanezumab) for Migraine Headache Prevention

September 17, 2018 Technology Prognosis

Ajovy (fremanezumab) is an injectable calcitonin gene-related peptide (CGRP) antagonist intended for the preventive treatment of migraine in adults. Ajovy is a monoclonal antibody that binds to CGRP ligands and blocks binding to CGRP receptors. CGRP is involved in vasodilation and sensory transmission and is a validated target for the treatment of migraine headache. Ajovy is administered via subcutaneous injection either monthly or quarterly;  it is available in prefilled single-dose syringes, and may be administered by health care professionals, patients, and/or caregivers.

GammaCore Transcutaneous Vagus Nerve Stimulator

September 6, 2018 Technology Prognosis

GammaCore is a noninvasive handheld prescription device intended to deliver transcutaneous vagus nerve stimulation for the acute treatment of pain associated with episodic cluster headache or migraine headache in adults. The device consists of a portable stimulator with a battery, signal-generating electronics, and a digital control user interface that controls signal amplitude. Two stainless steel round discs function as skin contact surfaces. A conductive gel is applied on the stimulation surfaces of the device prior to placement on the neck. The device delivers a mild electrical signal that is transmitted to the cervical branch of the vagus nerve; this stimulation...

Jivi (antihemophilic factor [recombinant] PEGylated-aucl)

September 5, 2018 Technology Prognosis

Jivi is an extended half-life PEGylated recombinant factor VIII product for routine prophylaxis, on-demand treatment, and intraoperative management of bleeding episodes in previously treated patients ≥ 12 years old with hemophilia A.

The Sonata Sonography-Guided Transcervical Fibroid Ablation System

August 29, 2018 Technology Prognosis

The Sonata Sonography-Guided Transcervical Fibroid Ablation System is a “next-generation” incisionless, intrauterine radiofrequency ablation (RFA) platform for the treatment of symptomatic uterine fibroids (the previous generation is known as VizAblate). The FDA cleared the Sonata System for market in August 2018. The system combines a miniaturized reusable intrauterine ultrasound probe and a single-use RFA handpiece that contains an introducer and needle electrode array. The RFA component also contains a proprietary graphical guidance software that provides the operating gynecologist with real-time graphic overlay on the live ultrasound image for treatment planning and precision. The RFA handpiece and intrauterine ultrasound probe snap...